1 Mar 2022 11:53
MGC Pharmaceuticals Ltd.
Compliance Statement - Prior Share Issues, Admission to Trading
1 March 2022
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') advises that following the RNS releases dated 10 February 2022 and 16 February 2022 for prior share issues between the Company's LSE Listing on 9 February 2021 and the Placing undertaken in December 2021, it is now applying for the admission to the Financial Conduct Authority's Official List, and to trading on the Main Market of the LSE for 20,613,270 Fully Paid Ordinary Shares issued by the Company from the December 2021 Placing up to today. The Company is seeking admission to trading for these shares from 8:00am (GMT) on Friday 4 March 2022.
The Company advises that the details of the 20,613,270 shares for which these applications are being lodged are as follows:
1. | 6/12/2021 | 750,000 shares issued as consideration for the extension of the maturity date of convertible notes issued by the Company. |
2. | 1/2/2022 | 1,440,117 shares issued as remuneration to an employee of the Company. |
3. | 1/2/2022 | 500,000 shares issued on the exercise of securities granted under the Company's Employee Share Scheme |
4. | 22/2/2022 | 17,923,153 shares issued as deferred purchase consideration to the vendors of MediCaNL Inc. |
The Company confirms that listing applications for all past share issues have been dealt with as a result of the above applications filed with the FCA and LSE. And advises that for future share issues by the Company, listing applications filed with the FCA and LSE, along with the requisite RNS release will be lodged at the time the shares are issued.
--Ends--
Authorised for release by the Chairman, for further information please contact:
MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au | MGC Pharmaceuticals Ltd David Lim Company Secretary +61 8 6382 3390 info@mgcpharma.com.au |
UK Broker - Turner Pope Andy Thacker +44 203 657 0050 info@turnerpope.com | UK PR Advisors - Tavistock Charles Vivian / Tim Pearson +44 207 920 3150 mgcpharma@tavistock.co.uk
|